Dulera

Discussion in 'GlaxoSmithKline' started by Anonymous, Jun 24, 2010 at 6:12 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    New Merck drug for asthma will be on shelves in July. This just means more PIPs. Get ready.
     

  2. Anonymous

    Anonymous Guest

    Now it get why more lay-off's later in year. Advair sales go down again. Next cutback at year end.
     
  3. Anonymous

    Anonymous Guest

    I love how I sat in a meeting just two months ago with my whole region and was told by some lady (wish I could remember her name) in Advair marketing that this drug had not been approved by the FDA and would probably not be out until 2012 at the earliest. How can you be so far off base with information like that? This drug will sink Advair.
     
  4. Anonymous

    Anonymous Guest

    Merck, whose shares were little changed in morning trade in New York, said it expected Dulera to be available in retail pharmacies across the United States by the end of July 2010. The drug is also being developed as a treatment for chronic obstructive pulmonary disease.
     
  5. Anonymous

    Anonymous Guest

    If they didn't see (or tell you about) Dulera getting approved, either GSK 'Leadership' was clueless about the market or hiding the truth from the field. Neither of which would be surprising.

    This drug will hurt GSK big time, in numerous ways.

    1. Now there are three drugs where there used to be one, & the pressure to reduce price will be huge. Someone, probably Symbicort because it's the weakest product of the three will undercut the managed care contracting price significantly. It's less profit or less volume, neither one is good for GSK.

    2. Specialists will embrace Dulera much quicker than Symbicort because Asmanex is a better Steroid than budesinide.

    3. Additionally, Schering (most Merck resp. specialty reps are Schering heritage) has had a long term presence with PUDs, Allergists and Peds for many years, where Astra Zeneca did not have those relationships to launch Symbicort.

    4. More samples on the shelves (from 3 competing drugs) mean that lots of business will walk out the door in sample bags. Long gone are the days where a rep could manage volume by starving an Advair supporter of samples.

    5. In many cases, lots of docs lost the rep that actually drove the business in the last re-org.
     
  6. Anonymous

    Anonymous Guest

    Unfortunately, you are right. I'm already on PIP from Q1-3 of '09. Haven't heard yet what going to happen in the look back on Q2 2009-Q4 2009, Q3 '09-Q1 '10, Q4'09- Q2 '10, Q1 '10-Q3 '10. Things are going to suck. I wish I had gotten package!!
     
  7. Anonymous

    Anonymous Guest

    As a RESP Rep, I am so happy I was deselected. Who needs the headache. The device data isn't doing it. Advair sales are going to continue to decline.
     
  8. Anonymous

    Anonymous Guest

    Wah wah, I want my mommy I am so scared. It is all over!
     
  9. Anonymous

    Anonymous Guest

    I can't wait to launch 'super advair' or advair xl or jalyn respiratory.... why didn't they come out with this much sooner?
     
  10. Anonymous

    Anonymous Guest

    Nice try Merckies!! First point; these are old drugs combined into one. second point;mometasone as first line therapy is a second or third choice at best. third point; AZ boy is the one worried about getting his lunch ate by this combo.
    Now go back to your own board or post on AZ board for your jollies.
     
  11. Anonymous

    Anonymous Guest

    Buddy, you better wake up. Advair's position is going to take a pretty big hit if Merck is aggressive with their pricing. Additionally, doctors like to try out their different options. Every medicine does a better job on certain patient types--they will want to find out where Dulera is best. Experimentation--and satisfaction?

    More lay offs by year end--I can almost guarantee it.
     
  12. Anonymous

    Anonymous Guest

    Sorry folks---the diskus data by itself isn't going to save Advair. Doctors already like mometasone and with faster agonist---why not!!!!!!???
     
  13. Anonymous

    Anonymous Guest

    UM, because the "faster agonist" is still for maintenance not rescue. WTF, these are old medications combined into one delivery device. Symbicort has an insignificant market share after three years. Nice try Merck boy!
     
  14. Anonymous

    Anonymous Guest

    You will see kool aid drinker fool!!!! Merck and their marketing dept are far superior. We will see what you say come about December.
     
  15. Anonymous

    Anonymous Guest

    You are crazy. Miami can't stop our passing game, and our o line is all 4 star or better. So bring on your blitz. Soften you up on a screen and a draw, and you will go back to VA. Ooops, wrong board.
     
  16. Anonymous

    Anonymous Guest

    What it all comes down to is advair is a dead man walking. In a year the advair market will go from 70% Advair 30% symbicort to 50% advair, 30% symbicort and 20 % dulera.

    Once this happens gsk will once again recognize they can't throw good money at bad. The days of bragging rights are over.

    And those who claim these drugs work better than one another I'd love to see the data. Until the FDA requires you show superiority it will not happen. So save the banter on who works better, the bottom line is price will drive this market and whoever is aggressive will win. GSK is bleeding to death so don't expect the purple passion to save you anymore.

    Let's be honest most doctors are also fed up with the no samplin advair reps. They are sick of the arrogance around gsk and respiratory. The tables are turning and it's not a good place to be if you sell advair.
     
  17. Anonymous

    Anonymous Guest

    Advair!!! what who
     
  18. Anonymous

    Anonymous Guest

    How do you spell it????
     
  19. Anonymous

    Anonymous Guest

    laid off in 2008from GSK.. will be promoting Dulers and already have Drs that will rx .Very very motivated and Merck is much better company now. My physicians will support this
     
  20. Anonymous

    Anonymous Guest

    None of it matters. When Advair goes generic - game over for the class. Bicker amongst yourselves....................